Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity

Circulation Research

Volumn 110, Issue 6, 2012, Pages 841-850

  Lovelock, Joshua D ^a,b   Monasky, Michelle M ^a   Jeong, Euy Myoung ^a   Lardin, Harvey A ^a   Liu, Hong ^a   Patel, Bindiya G ^a   Taglieri, Domenico M ^a   Gu, Lianzhi ^a   Kumar, Praveen ^a   Pokhrel, Narayan ^a   Zeng, Dewan ^c   Belardinelli, Luiz ^c   Sorescu, Dan ^b   Solaro, R John ^a   Dudley, Samuel C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Gilead   (United States)

Author keywords

diastole; myofilaments; oxidative stress; ranolazine

Indexed keywords

CALCIUM ION; DEOXYCORTICOSTERONE ACETATE; RANOLAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIASTOLIC DYSFUNCTION; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART MUSCLE CELL; HEART MUSCLE RELAXATION; HYPERTENSION; MOUSE; MYOFILAMENT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ACETANILIDES; ANIMALS; CALCIUM; DESOXYCORTICOSTERONE; DIASTOLE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HEART FAILURE, DIASTOLIC; MICE; MINERALOCORTICOIDS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; MYOFIBRILS; OXIDATIVE STRESS; PIPERAZINES; SODIUM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84862776882     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.258251     Document Type: Article

References (46)

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. (Pubitemid 44079340)
2. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202. (Pubitemid 36068707)
3. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA. 2006;296:2209-2216. (Pubitemid 44708051)
4. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544-2565. (Pubitemid 351670463)
5. Ouzounian M, Lee DS, Liu PP. Diastolic heart failure: mechanisms and controversies. Nat Clin Pract Cardiovasc Med. 2008;5:375-386. (Pubitemid 351935571)
6. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams KF Jr, Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397-403. (Pubitemid 44264821)
7. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53:184-192.
8. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.
9. Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. 2nd ed. Dordrecht/Boston: Kluwer Academic Publishers; 2001.
10. Ju YK, Saint DA, Gage PW. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol. 1996;497:337-347. (Pubitemid 26418103)
11. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. 1992;71:1231-1241.
12. Wu J, Corr PB. Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Physiol. 1994; 266:H1034-H1046. (Pubitemid 24121323)
13. Ward CA, Giles WR. Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol. 1997;500:631-642. (Pubitemid 27207825)
14. Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J Mol Cell Cardiol. 2008;44:954-967.
15. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. 2006;318:214-222.
16. Flagg TP, Cazorla O, Remedi MS, Haim TE, Tones MA, Bahinski A, Numann RE, Kovacs A, Schaffer JE, Nichols CG, Nerbonne JM. Ca2̈-independent alterations in diastolic sarcomere length and relaxation kinetics in a mouse model of lipotoxic diabetic cardiomyopathy. Circ Res. 2009;104:95-103.
17. Wolska BM, Kitada Y, Palmiter KA, Westfall MV, Johnson MD, Solaro RJ. CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction. Am J Physiol. 1996;270:H24-H32.
18. Pohlmann L, Kroger I, Vignier N, Schlossarek S, Kramer E, Coirault C, Sultan KR, El-Armouche A, Winegrad S, Eschenhagen T, Carrier L. Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res. 2007;101:928-938. (Pubitemid 350287180)
19. Davis J, Wen H, Edwards T, Metzger JM. Thin filament disinhibition by restrictive cardiomyopathy mutant R193H troponin I induces Ca2̈-independent mechanical tone and acute myocyte remodeling. Circ Res. 2007;100:1494-1502. (Pubitemid 46834762)
20. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, Boulden BM, Widder J, Fredd S, Bernstein KE, Wolska BM, Dikalov S, Harrison DG, Dudley SC Jr. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation. 2010;121:519-528.
21. Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20:131-138.
22. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents: Ranolazine Study Group. Am J Cardiol. 1999;84:46-50. (Pubitemid 29307639)
23. Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K, Hoffmann W, Poller W, Schultheiss HP, Pauschinger M, Tschope C. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation. 2007;116:637-647. (Pubitemid 47356348)
24. Maier LS. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late INa using ranolazine. J Cardiovasc Pharmacol. 2009;54:279-286.
25. de Tombe PP, Stienen GJ. Protein kinase A does not alter economy of force maintenance in skinned rat cardiac trabeculae. Circ Res. 1995;76:734-741.
26. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904-910. (Pubitemid 39136212)
27. Kass DA. Assessment of diastolic dysfunction. Invasive modalities. Cardiol Clin. 2000;18:571-586.
28. Yellin EL, Meisner JS. Physiology of diastolic function and transmitral pressure-flow relations. Cardiol Clin. 2000;18:411-433.
29. Hiranandani N, Bupha-Intr T, Janssen PM. SERCA overexpression reduces hydroxyl radical injury in murine myocardium. Am J Physiol Heart Circ Physiol. 2006;291:H3130-H3135. (Pubitemid 44904116)
30. Kuster GM, Lancel S, Zhang J, Communal C, Trucillo MP, Lim CC, Pfister O, Weinberg EO, Cohen RA, Liao R, Siwik DA, Colucci WS. Redox-mediated reciprocal regulation of SERCA and Naβ-Ca2̈exchanger contributes to sarcoplasmic reticulum Ca2̈depletion in cardiac myocytes. Free Radic Biol Med. 2010;48:1182-1187.
31. Wagner S, Seidler T, Picht E, Maier LS, Kazanski V, Teucher N, Schillinger W, Pieske B, Isenberg G, Hasenfuss G, Kogler H. Naβ- Ca2̈exchanger overexpression predisposes to reactive oxygen species-induced injury. Cardiovasc Res. 2003;60:404-412. (Pubitemid 37412374)
32. MacFarlane NG, Miller DJ. Effects of the reactive oxygen species hypochlorous acid and hydrogen peroxide on force production and calcium sensitivity of rat cardiac myofilaments. Pflugers Arch. 1994;428:561-568. (Pubitemid 24321875)
33. Wang H, Kohr MJ, Traynham CJ, Wheeler DG, Janssen PM, Ziolo MT. Neuronal nitric oxide synthase signaling within cardiac myocytes targets phospholamban. Am J Physiol Cell Physiol. 2008;294:C1566-C1575.
34. Monasky MM, Varian KD, Davis JP, Janssen PM. Dissociation of force decline from calcium decline by preload in isolated rabbit myocardium. Pflugers Arch. 2008;456:267-276.
35. LeWinter MM. Functional consequences of sarcomeric protein abnormalities in failing myocardium. Heart Fail Rev. 2005;10:249-257.
36. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L, Maier LS. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 2008;45:32-43.
37. Hwang H, Arcidi JM Jr, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, Kloner RA. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation. 2009;120:S16-S21.
38. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28:1231-1237. (Pubitemid 24264731)
39. Maruyama K, Hara A, Hashizume H, Ushikubi F, Abiko Y. Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol. 2000;52:709-715. (Pubitemid 30410085)
40. Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17:S169-SS177.
41. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O, Biesiadecki BJ, Blackburn B, Wolff A, Stanley WC. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail. 2002;8:416-422. (Pubitemid 36055744)
42. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, Stanley WC, Sabbah HN. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol. 2008;295:H2149-H2155.
43. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther. 1994;8:741-747. (Pubitemid 24376754)
44. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19:1289-1293.
45. Hinken AC, Solaro RJ. A dominant role of cardiac molecular motors in the intrinsic regulation of ventricular ejection and relaxation. Physiology (Bethesda). 2007;22:73-80.
46. Tong CW, Stelzer JE, Greaser ML, Powers PA, Moss RL. Acceleration of crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein C modulates cardiac function. Circ Res. 2008;103:974-982.